Tumor Targeting by Conditioned Medium Derived From Human Amniotic Membrane: New Insight in Breast Cancer Therapy

Ameneh Jafari1, Mostafa Rezaei-Tavirani1, Hassan Niknejad2, and Hakimeh Zali1,3

Abstract

Objectives: Traditional breast cancer treatments have challenges including inefficiency, multidrug resistance, severe side effects, and targeting non-specifically. The development of alternative treatment strategies has attracted a great deal of interest. Using the amniotic membrane has become a promising and convenient new approach for cancer therapy. This study aimed to evaluate the anti-cancer ability of conditioned medium extracted from the human amniotic membrane (hAM-CM) on breast cancer cells.

Methods: Conditioned medium was collected after 48 h incubation of hAM in epithelial up manner. MTT, cell cycle, apoptosis, colony formation, and sphere assays were used to determine the impact of hAM-CM on breast cancer cell lines. The effects of hAM-CM on the migration and invasion of breast cancer cells were determined using scratch wound healing and transwell assays, respectively.

Results: Based on the results, cell viability was significantly decreased by hAM-CM in a dose-dependent manner. The hAM-CM remarkably induced apoptosis and necrosis of cancer cells. Moreover, cell migration and invasion potential of cancer cells decreased after the hAM-CM treatment. Further, both the number of colonies and their morphologies were affected by the treatment. In the treated group, a significant decrease in the number of colonies along with an obvious change in their morphologies from holoclone shape to a dominant paracolone structure was observed.

Conclusion: Our results indicate that the conditioned medium derived from the human amniotic membrane able to inhibit proliferation and metastasis of tumor cells and can be considered a natural and valuable candidate for breast cancer therapy.

Keywords

amniotic membrane conditioned medium, breast cancer, apoptosis, migration, invasion

Received: September 21, 2020; Revised: April 22, 2021; Accepted: May 26, 2021.

Introduction

Breast cancer is the most common cancer among women worldwide, accounting for a quarter of all cancers, and causing the largest number of cancer-related deaths among women as well.1,2 The World Health Organization (WHO) estimated that 627,000 women died from breast cancer in 2018—nearly 15% of all women’s cancer deaths.3 In 2020, there were an estimated 276,480 new cases of invasive breast cancer and 42,170 deaths from breast cancer in women in the United States.4 It is estimated that 1.6 million breast cancer cases occur per year globally, making it currently the most common cancer in women.5 According to studies, 10% of women over the age of 55 are diagnosed with breast cancer.6 While several conventional therapies are available, none of them is completely successful and effective.7,8 Moreover, due to the heterogeneity of cancer cells, their spread by the blood and lymph, the presence of cancer stem cells, and increased drug resistance, breast cancer often characterized by relapse or metastasis.9 These challenges, along with the increasing trend of breast cancer in the last few years, have raised the need for new effective treatment strategies.

1 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Corresponding Author:
Hakimeh Zali, Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Email: hakimehzali@gmail.com
decade, make it fundamentally urgent to find more rational, efficient, innovative, and low-cost treatments.\textsuperscript{10,11} Within this context, many novel strategies, especially those relating to stem cell biology, have been widely considered.\textsuperscript{11-13} One of the exciting new ideas for stem cell cancer therapy is the possibility of using the amniotic membrane (AM).\textsuperscript{13} Extensive research is focused on the AM as a potentially unlimited source of stromal cells that allow cell collection through simple, safe, non-invasive, and cost-effective methods compared to other stem cell sources such as bone marrow.\textsuperscript{14}

Amnion, the innermost layer of embryo membranes with a particular structure, providing an immunologically, anatomically, and physiologically privileged space for the growth and development of the fetus.\textsuperscript{15} Amniotic membrane cells include amniotic epithelial (hAECs) and mesenchymal cells (hAMSCs) with stemness features that are remarkable for cellular therapies and regenerative medicine. The human amniotic membrane (hAM) is consisting of 5 layers: epithelium, basement membrane, compact layer, fibroblast layer, and spongy layer, as illustrated in Figure 1.\textsuperscript{13,16} The AM has been employed for numerous applications, including ophthalmology to treat corneal, disorders associated with the urinary tract, head and neck, oral cavity, burns, scars as well as general surgery to reconstruct artificial vaginal, skin, and other surfaces reconstruction.\textsuperscript{17-24} The hAM is well known for its attractive and promising properties, such as anti-inflammatory,\textsuperscript{25,26} antimicrobial,\textsuperscript{27} and antiangiogenic properties,\textsuperscript{28} as well as low immunogenicity\textsuperscript{26} and non-ethical concerns.\textsuperscript{16,26} Furthermore, it is discarded after childbirth and is easily accessible without costly procedures.\textsuperscript{16,29} These beneficial properties make the amniotic membrane an ethically acceptable and unique candidate for a variety of biomedical applications, from regenerative medicine, tissue engineering, and drug reservoir to cancer therapy.\textsuperscript{16,30,31} The anti-proliferative effect of amniotic membrane cells was demonstrated on various cells such as immune and cancer cells.\textsuperscript{32-34} Amnion could suppress the proliferation of the immune cells, induce the apoptosis of B and T lymphocytes by the secretion of soluble factors including tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), transforming growth factor-\(\beta\) (TGF-\(\beta\)), Fas ligand (FasL), TNF-related apoptosis-inducing ligand (TRAIL), and macrophage migration inhibitory factor, as numerous studies have demonstrated.\textsuperscript{35-37} Furthermore, the evidence has been revealed the antiangiogenic and cell cycle inhibitory properties of amnion.\textsuperscript{14,38,39} Some recent studies have speculated antitumor properties not only for human amniotic stromal cells but also for intact hAM and its conditioned medium.\textsuperscript{40,41} Accordingly, the present study aims to study the anticancer effects of the human amniotic membrane conditioned medium (hAM-CM) on breast cancer cell lines. Our findings may provide new insight into breast cancer treatment by demonstrating the anticancer properties of conditioned medium derived from the human amniotic membrane.

**Materials and Methods**

**Preparation of Amniotic Membrane**

Human placentas (n = 25) were obtained from healthy donor mothers after the cesarean section following normal term pregnancies (37-40 weeks of gestation). Placentas were collected after obtaining informed written consent from all subjects according to the guidelines set by the Ethical Committee of Shahid Beheshti University of Medical Sciences. The results for syphilis, HCV, HBV, and HIV tests for mothers were negative. The placenta immediately was transported to the laboratory in a sterile bag containing normal saline at 4°C. After the reception, the amnion was manually separated from the chorion by peeling and washed 3 times with cold phosphate-buffered saline (PBS) to remove blood.

**Culture of the Amniotic Membrane**

The AM was cut into 2 \(\times\) 2 cm\(^2\) pieces. The AM pieces were put at the bottom of 12 well plates in the epithelial side up position and fixed with a glass ring (diameter 1cm). Then they
were incubated with 1 ml of completed Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM-F12) medium DMEM-F12 (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin-streptomycin (Sigma Aldrich).

Preparation of Amniotic Membrane Conditioned Medium
In order to obtain CM from AM, after 24 hours of incubation at 37°C and 5% CO2, the supernatant of each well was collected and filtered through a 0.45 µm sterile filter to remove cell debris. The collected CM from the different hAM (from 25 different placenta donors) was pooled and used in subsequent experiments.

Culture of Breast Cancer Cell Lines
Human breast cancer cell lines include MCF-7, MDA-MB-231, and BT-474, and the human normal epithelial breast cell line MCF10A were bought from the cell bank of Iran’s Pasteur Institute. The MCF10A cells were cultured in DMEM/F12 media supplemented with 5% horse serum, 20 ng/mL epidermal growth factor (EGF), 0.5 mg/mL hydrocortisone, 100 ng/mL cholera toxin, 10 µg/mL insulin and 1% Pen/Strep. The cancer cells were cultured in a completed DMEM-F12 medium and incubated in 95% humidified air containing 5% CO2 at 37°C. After reaching 80% confluence, the cells were detached using trypsin-EDTA (Sigma-Aldrich) and sub-cultured in 96-well plates (1 x 104 cells/well) for 24 h.

The Effects of hAM-CM on the Viability of Breast Cancer Cell Lines
After 24 h, the medium was replaced with hAM-CM pure or diluted in a ratio of 3:4 (3/4), 1:2 (1/2), and 1:4 (1/4) with a complete culture medium. An untreated group of cancer cells that incubated with a complete culture medium was considered as a control group. Every experiment was repeated 3 times. In order to determine the proliferation of cells, the viability of cancer cells was measured after 24, 48, and 72 h in all groups by 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, the 0.5% MTT solution (5 mg of MTT per 1 ml of distilled water) was sterilized by a 0.22 µm filter and added to cancer cells. Then the cell culture plates were incubated at 37°C for 4 h. Afterward, the formazan crystals were dissolved in DMSO, and the optical absorption of dissolved formazan was measured at the wavelengths of 570 nm and 630 nm (as reference), using a spectrophotometer (Bio-Rad) to determine the percentage of live cells. The optical density of treated and untreated were measured and converted in cell viability (CV) percentages using the following formula:

\[ CV(\%) = \frac{\text{Sample optical density}}{\text{Control optical density}} \times 100 \]

Apoptosis Analysis
In this study, MDA-MB-231 breast cancer cells were cultured in a completed DMEM-F12 medium in a T25 culture flask (in triplicate for experiments). After reaching 85% confluence, the culture medium was changed by hAM-CM (in triplicate for experiments). These cells were used for apoptosis and cell cycle analysis. The MDA-MB-231 cells cultured in complete DMEM-F12 medium (without hAM-CM) were used as control. For cell apoptosis distinguish, after 48 h (the optimal time for incubation was determined based on the previous experiment), cells were harvested and analyzed by Annexin-V and propidium iodide (PI) staining, using the FITC Annexin V apoptosis detection kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions. Especially, cancer cells were washed twice with cold PBS and centrifuged (2000 rpm, 5 min, RT). After removing the supernatant, the cell pellet was resuspended in 100 µl of binding buffer and incubated at room temperature with Annexin-V FITC and PI solutions. Then 400 µl binding buffer was added, and cells were analyzed using a FACS Calibur Flow cytometer. Data were analyzed with CellQuest 3.3 (BD Biosciences, San Jose, CA). Results were reported as the percentage of Annexin V+ (early apoptosis), PI+ (necrosis), Annexin V+PI+ (double-positive; late apoptosis) cell population. The percentage of Annexin V-PI- (double negative; non-stained) cell population is considered as viable cells.

Cell Cycle Analysis
Flow cytometry was used to investigate how cell cycle distribution is influenced by hAM-CM. MDA-MB-231 cells (5 x 105 cells) were treated with hAM-CM and incubated for 48 hours. At the end of treatment time, cells were detached using trypsin-EDTA 0.2% and centrifuged. Subsequently, the cells were collected, washed with ice-cold PBS, fixed with 70% alcohol at 4°C for 12 h and stained with PI in the presence of 1% RNAase A at 37°C for 30 min before analysis using flow cytometry (BD Biosciences, San Jose, CA, USA). CellQuest 3.3 software was used to analyze the percentage of cells in G1, S, and G2 phases.

Scratch-Induced Migration Assay In Vitro
The scratch-wound healing assay as a convenient and promising method was used to assess and quantify the effects of hAM-CM treatment on cancer cell migration. The MDA-MB-231 cells (7 x 104 cells/well) were seeded in 24 well plates and allowed to attach, spread, and confluent. When reaching 80%-90% confluence, these cells were treated with hAM-CM ¼ for 48 h. Then, the cells were incubated with mitomycin (0.5mg/ml) for 2 h and wounded by the tip of a sterile 200 µl micropipette. Each well was washed twice with PBS to remove all separated cells. Cell migration rate was photographed at 0 and 24 h using an inverted microscope (Nikon, ECLIPSE, TE 2000-4, Japan). Manual counting quantified the migrated cells. The edge
of scratch determines then measures the scratch line in 0, and 24 h. For the better resolution of the scratch line in each group at 0 and 24 h, one well was fixed by paraformaldehyde (4%) for 20 min and stained with 1% crystal violet (dissolved in 2% ethanol). The scratch line in 24 h mines from 0 h and data are presented as mean scratch line ± SD relative to untreated controls (n = 3 independent experiments). The results are presented as the percentage of wound healing, which was calculated as follows: \( \frac{\text{Wound area (initial)} - \text{Wound area (final)}}{\text{Wound area (initial)}} \times 100 \).

**Transwell Migration and Invasion Assay**

We used transwell assay and Matrigel transwell to evaluate migration and invasion potential of MDA-MB-231 cells, respectively. Cell migration assays were performed using inserts with 8-µm pore-sized membranes in a 24-well plate (Corning Costar, Lowell, MA, USA). The MDA-MB-231 cells, which were pretreated with CM for 2 days, were used as an experimental group and untreated cells as a control group. The cells (25,000 cells/insert) were placed in the upper chamber in serum-free DMEM-F12. Then the lower chamber was covered with 600 µL of the complete DMEM-F12 medium as a chemottractant, and the plate was incubated at 37°C in 5% CO2. After 24 h incubation, non-migratory cells were wiped out from the upper side of the filter using a cotton swab. Migratory cells at the bottom side of the filter were washed with PBS, fixed with 4% paraformaldehyde for 10 min, stained with 1% crystal violet (dissolved in 2% ethanol) for 10 minutes, and photographed. Photos were taken from 3 randomly selected regions/well, then cells were counted, and the mean number of migrated cells was calculated. All of the experiments were performed in triplicate. The percent of migration was calculated using the following formula: \( \frac{(\text{The number of cells per insert}) - (\text{Total number of cell-seeded})}{(\text{Total number of cell-seeded})} \times 100 \).

For invasion assay, the transwell 24-well insert plate was pre-coated with Matrigel (Corning) at 0.3 µg × µL−1 per well at 37°C overnight. Pretreated and control groups of MDA-MB-231 cells were seeded (25,000 cells/well) onto the insert as described for migration assay. Then the plate was incubated in a 37°C humidified atmosphere and 5% CO2 for 24 h. After that, the invaded cells were stained and counted as described above. The percent of invasion was calculated by the following formula: \( \frac{(\text{The number of cells per insert}) - (\text{Total number of cell-seeded})}{(\text{Total number of cell-seeded})} \times 100 \).

**Clonal Survival Assay**

The MCF7 breast carcinoma cells were selected as a better cell line for showing colony formation. Cells were pretreated with hAM-CM 75% dilution (hAM-CM ¼) for 48 h. Then cells were seeded in a 6-wells plate (1000 cells/well) and incubated in DMEM-F12 10% FBS for 7 days. These cells were applied as pretreated and untreated cells as a control group. After a week, paraformaldehyde was used to stable the colonies and crystal violet was applied to stain the mixture. Phase-contrast microscopy was to specify the number of colonies, and shapes in each plate. Data are presented as mean colony number ± SD relative to untreated controls.

**Spheroid Assay**

Breast cancer cell lines, including MDA-MB-231 and MCF7, were selected for spheroid formation assay. Both cell lines were treated with hAM-CM 75% diluted (as CM-treated group) or completed DMEM/F12 medium (as a control group) during 48 h. Two percent (w/v) gel agarose was prepared by dispersing powder of agarose (Sigma) in distilled water and autoclaving of solution for sterilization. When the solution was still liquid, 500 µL of the solution was pipetted into each well of the 12-well plate. After solidification, 1 ml cell suspension containing 3 × 104 treated or untreated cells were carefully seeded into each well. After 4 days of incubation, the total number of spheroids larger than 100 µm was manually counted in under a phase-contrast microscope using the 40 × magnification lens. The number of spheroids was counted and compared to the initial number of seeded cells.

**Statistical Analysis**

All experiments were repeated 3 times. Data were presented as mean ± standard deviation (SD). The results were analyzed using a 1-way analysis of variance (ANOVA) to identify the level of significance between different treatment groups relative to control. Statistical values were performed using Graph Pad 8.0 (GraphPad Software, Inc., La Jolla, CA, USA). All tests were considered significant for \( P \) values ≤ 0.05. At the figure legends, the asterisks denote statistically significant differences between the treatments (*\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \), ****\( P < 0.0001 \)).

**Results**

To study the effects of conditioned medium derived from the amniotic membrane on viability, apoptosis, migration, and invasion of human breast carcinoma cells, according to previous studies, we selected some critical tests.

**Effect of hAM-CM on Cell Proliferation**

To examine the effect of hAM-CM on cancer and non-cancer cell growth, a MTT assay was performed. The viability of breast cancer cells decreased after treatment with hAM-CM in a time-dependent manner, while in the number of viable cells of the non-cancer MCF10A cells a slight increase was observed (Figure 2A). After treatment for 48 h, a significant decrease in the percentage of viable cells was observed in 3 cancer cell lines as compared to controls, reaching a 72% reduction in MCF-7, 65.5% in MDA-MB-231, and 56.3% in BT-474 cells. As presented in Figure 2B, treatment with different concentrations of hAM-CM reduced the cell viability of cancer cells in a dose-dependent manner compared with the untreated cancer cells.
Effect of hAM-CM on Apoptosis Process

To better understand the mechanism involved in the anti-proliferative activity of hAM-CM, we performed apoptosis analysis. After treatment of MDA-MB-231 cells by hAM-CM, the number of Annexin V-stained cells was determined using flow cytometry. Regarding the results, apoptotic cells in the hAM-CM-treated group were significantly higher than the control group (33.6% vs 2.7%). After treated with hAM-CM, the viable cell population considerably diminished from 87% in the control group to 55% in the hAM-CM-treated group (Figure 3).

Effect of hAM-CM on Cell Cycle Phase Distribution

The relative percentages of MDA-MB-231 cells in each phase of the cell cycle following treatment with hAM-CM have been showing in Figure 4A. Our results showed that hAM-CM could suppress cell growth, and resulted in a noteworthy accumulation of cells in G2/M accompanied by a decrease in S and G0/G1 DNA content (Figure 4A). After the exposure of MDA-MB-231 cells to hAM-CM for 48 h, the percentage of cells in the G2/M phase dramatically increased from 9.3% to 24%. Moreover, cells in G1 diminished from 45.6% (untreated group) to 35.3% (hAM-CM-treated group) (Figure 4B).

Effect of hAM-CM on the Migration Ability of Breast Cancer MDA-MB-231 Cells

From the results, the hAM-CM significantly inhibited the migration of MDA-MB-231 cells in comparison with the control (untreated) group (Figure 5A). The mean percentage of wound healing in the control and treated group was calculated 44% ± 3.4% and 12% ± 2.7%, respectively (Figure 5B).
was suggested that the medium containing hAM-CM could inhibit migratory abilities.

**Effect of hAM-CM on Migration and Invasion Potential of Breast Cancer MDA-MB-231 Cells**

As depicted in Figure 6A, the transwell assay indicated that hAM-CM dramatically reduced cell invasion significantly compared with the control group (untreated group). According to the results, after exposure to the conditioned medium, the percentage of invasive cancer cells decreased from 43% to 28% (Figure 6B). Moreover, the migration capacity of pretreated cancer cells was significantly less than control cancer cells (Figure 7A). Our results showed that the migration rate in treated cells was 5.7 times lower than the control group (Figure 7B).

**Clonal Survival Following hAM-CM Treatment**

Clonal survival assays were carried out on MCF7 cells treated with hAM-CM and compared with the control group. By this approach, we could assess the impact of factors in hAM-CM on the clonogenicity of cancer cells. All 3 colony types, including, holoclones, meroclones and, paraclones, were observed in groups. Data showed that the number and the shape of colonies, are different between control and treated groups (Figure 8A). As illustrated in Figure 8B, the number of colonies in hAM-CM treated cells was dramatically reduced compared to untreated cells. Moreover, in the control group, most colonies are in the

![Figure 4](image_url)

**Figure 4.** To study the cell cycle phase distribution in MDA-MB-231 cells with and without treatment, PI staining was performed; then flow cytometry analysis was run. Testing cell cycle qualitatively (A), and quantitatively (B) shows the presence of the G2/M phase arrest, which there is a significant difference between control and treated groups. In the G0/G1 phase also there is significant difference between groups. *P < 0.05, **P < 0.01.

![Figure 5](image_url)

**Figure 5.** A, Qualitative scratch test was used to investigate the migration ability of MDA-MB-231 cells comparing with the control (untreated group). B, The quantitative scratch test represented that the migration of the hAM-CM treated group was inhibited more than the control group. ***P < 0.001.
form of holoclone, while in the treated group, they are the paracolone shape.

**Effect of hAM-CM Treatment on Sphere Formation**

The impact of hAM-CM on sphere formation potential in MCF-7 and MDA-MB-231 cells was assessed. The percentage of tumorspheres represents the CSC subpopulation in culture.

Regarding the results, the number of spheres in the CM-treated group decreased sharply (Figure 9A). The sphere formation rate in the treated groups was approximately 3 times lower than the control groups (Figure 9B). Interestingly, the number of spheres in MDA-MB-231 cells was almost twice that of MCF-7 cells.

**Figure 6.** Regarding qualitative transwell invasion assays in (A) transwell invasion assays were as used to investigate the invasion potential of MDA-MB-231 cells in comparison with control (untreated). (B) Quantitative transwell invasion represented the inhibitory effects of hAM-CM on cell invasion potential. **P < 0.01.

**Figure 7.** A, Qualitative transwell migration assays were used to investigate the migration potential of MDAMB-231 cells in comparison with control (Untreated). B, Quantitative transwell migration represented the inhibitory effects of hAM-CM on cell migration potential. ****P < 0.0001.
Discussion

The discovery of successful cancer treatments has long been one of the scientific challenges. In this light, we investigated the anticancer properties of the conditioned medium derived from the human amniotic membrane on the breast cancer cell lines. The data shows that the hAM-CM has anti-proliferative effects against breast cancer cells in a dose-time-dependent manner and significantly decreases the viability of breast cancer cells while enhancing the proliferation of non-tumorigenic mammary cells MCF10A. This result is in accordance with our data published earlier. Previously, we obtained the same results for Hela cervical cancer cells and MDA-MB-231 breast cancer cells after exposure with the fresh and cryopreserved hAM supernatant. Riedel and coworkers reported that hAM-CM diminishes cell viability and cell number of hepatocarcinoma HepG2 cells. However, the authors did not observe any change in the viability of non-liver cell lines, especially MCF-7, after treatment with hAM-CM. We speculate this difference in results is due to a difference in the nature of CM. Conditioned media in our study contained soluble factors that were mostly released from hAECs, whereas CM in that study was derived from 2 major human amniotic membrane cell types.

Based on our results, BT-474 cells seem to be more sensible to hAM-CM treatment than MDA-MB-231 and MCF-7 cells, since viability diminution is noticeably higher in the former. The reason probably is due to the difference between these cell

---

**Figure 8.** Clonogenicity of MCF7 cells following the treatment with and without hAM-CM was assessed by colony formation assay. A, Regarding the qualitative colony assay test in the number of the colony was decreased in treated groups. B, Regarding the quantitative colony test changing in the colony, the shape is observed after treatment with hAM-CM. ***P < 0.001.

**Figure 9.** The effect of hAM-CM treatment on sphere formation in cancerous cells. A, The sphere shape in control, and treated groups of MDA-MB-231 cells. B, hAM-CM decreases sphere formation in MCF-7 and MDA-MB-231 cells. Representative results of the sphere formation of these cells treated with hAM-CM compared with pre-treated and untreated cells (as a control group). **P < 0.01.
lines. As these cell lines diverge in their molecular features, therefore they show different responses to chemotherapeutic agents. The BT-474 cell is classified as HER2 positive, while MDA-MB-231 and MCF-7 cells are HER2 negative cells. Comparing to HER2-negative tumors, breast carcinoma cells with HER2 overexpression have higher proliferation and motility rates, and increased sensitivity to certain drugs.

In this paper, we demonstrated the impact of hAM-CM on migration, invasion, and clonogenicity, and sphere formation of the MDA-MB-231 cell line. This cell line is an adherent epithelial triple-negative cell line that likely contains more than one cell population, and it is a highly aggressive, invasive, and poorly differentiated human breast cancer cell line, making it appropriate for our experimental designs.

Apoptosis is considered a protective mechanism against cancer development and an important way of cell death after treatment with the cytotoxic drug in a variety of cancer types. Interestingly, our flow cytometry analysis showed that the percentages of apoptotic cells in MDA-MB-231 cells treated with hAM-CM were significantly higher than that in the control group. In a prior study, we observed the upregulation of pro-apoptotic proteins (caspase-3 and caspase-8) in cancer cells after treatment with AM supernatant. We thus concluded that the hAM-CM effectively causes the death of cancer cells through the induction of apoptosis. Amniotic membrane-released factors, such as TNF-α, TNF-β, interferon-γ, the interleukins (ILs), and prostaglandin E2 might be induced apoptosis of tumor cells.

Inhibition of cell cycle progression is a key strategy for the regulation of cell growth. The G2/M phase cell cycle arrest is a promising therapeutic approach in the battle against cancer. Obtained results indicated that treatment with hAM-CM for 48 h led to a decrease in the percentage of cells in the G0/G1 phase and a notable increase in cells in the G2/M phase.

Considering these results, it can be concluded that hAM-CM successfully reduced the growth of treated cancer cells through G2/M cell cycle arrest and preventing the progression cell cycle from G2/M to G1.

Since active biomolecules, such as proteins, exosomes, microRNA, or prostaglandins could exerting key actions, we evaluated the effects of all the released soluble factors by the AM. Mamede et al. in their study demonstrated that the AM-extracted proteins could inhibit the metabolic activity of cancer cell lines after 3 days. This extract also could induce apoptosis of hepatocarcinoma cell lines by decrease the content of protein and DNA. Another paper also reported that AM-CM could inhibit cell cycle progression and DNA synthesis in hepatocarcinoma cells. The authors attributed these effects to a decrease in Cyclin D1 and Ki-67 expression, and an increase in expression of p21 and p53 along with the modulation of pro and antitumoral microRNAs.

Intriguing results obtained in this study demonstrated that hAM-CM can inhibit the migration of MDA-MB-231 cells and their invasion. The migration and invasion of cancer cells led to metastasis and the spread of the tumor cells to other tissues. Metastasis is a fundamental challenge for cancer therapy, so inhibition of the invasion process by hAM-CM will be very useful in overcoming cancer progression. However, further experiments are needed to get deeper thinking about the mechanisms involved in inhibiting cancer cell migration and/or invasion by hAM-CM.

The obtained results are inconsistent with the data reported by some studies that have examined the effect of AM on cell migration. For example, a recently published study demonstrated the influence of AM in an epithelial down manner on the migration rate of mink lung epithelial cells (Mv1Lu) and human keratinocyte cell line (HaCaT) cells. The results indicated the AM can induce migration of these cells in a process that involves the activation of c-Jun phosphorylation, which requires MEK1 and JNK signaling to exert this effect. The authors also reported the modulating of TGF-β-Smad signaling by AM in the migration of Mv1Lu and HaCaT cells. Our results are also contrary to the results of Kim and co-workers. They reported increased proliferation and migration rates in MDA-MB-231 and MCF-7 cell lines after exposure to the conditioned medium. Zhang et al. revealed that hAEC-CM contains some enriched cytokines, such as TGF-β1, BMP15, GDF9, which are involved in the process of pro-angiogenesis, anti-apoptosis, and regulation of cell cycle and follicle development in the injured ovary. The reasons for these discrepancies are uncertain, though they may be due to the composition of the conditioned medium. In recent studies, the authors applied AM in an epithelial down manner or conditioned medium derived from amniotic cells, while we used the harvested conditioned medium from intact AM in the epithelial side up manner. It is reported that the epithelial side of hAM suppresses angiogenesis, while the mesenchymal side of hAM raises angiogenesis. Moreover, the incubation time and culture medium used to generate the conditioned media are other variables to consider. Therefore, the diversity in CM composition produced by the various protocols probably highlights the functional changes in the effect of hAM-CM on cancer cells. For each case, additional tests would be required to determine its composition.

We set out the colony-forming assay to identify the impact of hAM-CM on the clonogenicity of MCF-7 breast cancer cells. It is well known 3 clone types include holoclone, meroclone and paraclone correspond to stem and early and late amplifying cells, respectively. It has been shown that holoclone cells are smaller, more highly clonogenic, and more adherent than paraclone cells. Holocones are contained highly proliferative, self-renewal, and immortal cells. An increased number of holoclones in the control group probably is regarded as enrichment for undifferentiated and self-renewing cancer stem cells (CSCs). These cells are usually considered eternal combined with a high potency of cell division, which leads to tumor growth and metastasis. According to the present study, the use of hAM-CM can be very effective in preventing tumor growth and inhibition of metastasis via targeting CSCs. CSCs have been revealed able to form 3D spheres in vitro when they grow in non-adherent serum-free conditions. The sphere formation assay offers a useful tool to assess the
population of tumors or cancerous cell lines. Several reports have been indicated that the results from the sphere are more reliable than those from 2D monolayer cultivation and can better mimic the microenvironment in primary tumors.\textsuperscript{63} In 2D cultivation, cells were grown as monolayer while in spheres as a cluster.\textsuperscript{64} The 3D microenvironment has been well established in modifying various cellular and functional activities, like hypoxia, viability, proliferation, differentiation, migration, and drug sensitivity.\textsuperscript{65} To evaluate whether hAM-CM could change the sphere formation efficacy, its effects on MDA-MB-231 and MCF7 cells were analyzed. We found a steady decrease in the number of spheres in both cell lines after treatment. Given these findings, hAM-CM may contain some factors with anti-CSC agents. The doubling of the number of spheres in MDA-MB-231 cells compared to MCF-7 cells indicates a greater number of CSCs in the MDA-MB-231 population than in MCF-7.

In conclusion, our data indicate that conditioned medium delivered from the epithelial side of the human amniotic membrane probably contains soluble factors responsible for triggering an anti-tumor response. The present study showed that cell proliferation inhibition due to the treatment with hAM-CM correlated with G2/M phase arrest and was followed by breast cancer cell apoptosis. Our findings, with the outline of the anti-cancer effects of the hAM-CM, will open up a new avenue for cancer treatment. In this case, the current study suggests the opportunity to use this conditioned medium as a novel, natural, safe, and low-cost strategy for breast cancer therapy, without any ethical and technical issues. Therefore, the hAM-CM could be a promising target compound for developing a new anti-cancer drug. Nevertheless, further studies are warranted to identify the active compounds responsible for the anti-proliferative activities of hAM-CM and its potential as a novel anti-cancerous agent in vivo.

**Authors’ Note**

Our study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (Ethics Code: IR.SBMU.REC.1394.84). All participants provided written informed consent prior to enrollment in the study. This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Subjects have given their written informed consent and the Ethical Committee of Shahid Beheshti University of Medical Sciences approved the study protocol.

**Acknowledgments**

This study was part of a PhD project conducted at Shahid Beheshti University of Medical Sciences. This study was supported by School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences (No. 4887).

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences (No. 4887).

**ORCID iD**

Ameneh Jafari @ https://orcid.org/0000-0002-8165-5978

**References**

1. Jafari-Oliayi A, Asadi MH. SNHG6 is upregulated in primary breast cancers and promotes cell cycle progression in breast cancer-derived cell lines. *Cell Oncol*. 2019;42(2):211-221.
2. Wendt C, Margolin S. Identifying breast cancer susceptibility genes—a review of the genetic background in familial breast cancer. *Acta Oncol*. 2019;58(2):135-146.
3. Rahman SA, Al-Marzouki A, Otim M, Khayat NEHK, Yousef R, Rahman P. Awareness about breast cancer and breast self-examination among female students at the University of Sharjah: a cross-sectional study. *Asian Pac J Cancer Prev*. 2019;20(6):1901.
4. Rebecca L SR, Kimberly D, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7-30.
5. Thorat MA. Best practice and research clinical obstetrics and gynaecology. Preface. *Best Pract Re Clin Obstet Gynaecol*. 2020;65:18-31.
6. Lu X, Kang Y. Organotropism of breast cancer metastasis. *J Mammary Gland Bio*. 2007;12(2-3):53.
7. Jafari A, Rezaei-Tavirani M, Salimi M, Tavakkol R, Jafari Z. Oncological emergencies from pathophysiology and diagnosis to treatment: a narrative review. *Soc Work Public Health*. 2020;35(8):689-709.
8. Waks AG, Winer EP. Breast cancer treatment: a review. *JAMA*. 2019;321(3):288-300.
9. Koch U, Krause M, Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures—radiation oncology perspective. *Semin Cancer Biol*. 2010;20(2):116-124. Elsevier.
10. Jafari A, Babajani A, Abdollahpour-Alitappeh M, Ahmad N, Rezaei-Tavirani M. Exosomes and cancer: from molecular mechanisms to clinical applications. *Med Oncol*. 2021;38(4):45-61.
11. Zhang CL, Huang T, Wu BL, He WX, Liu D. Stem cells in cancer therapy: opportunities and challenges. *Oncotarget*. 2017;8(43):75756.
12. Jafari A, Rezaei-Tavirani M, Farhadhosseinabadi B, Taranejoo S, Zali H. HSP90 and co-chaperones: impact on tumor progression and prospects for molecular-targeted cancer therapy. *Cancer Invest*. 2020;38(5):310-328.
13. Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. *Cytotherapy*. 2014;16(1):33-40.
14. Kim SH, Bang SH, Kang SY, et al. Human amniotic membrane-derived stromal cells (hAMSC) interact depending on breast cancer cell type through secreted molecules. *Tissue Cell*. 2015;47(1):10-16.
15. Seo JH, Kim YH, Kim JS. Properties of the amniotic membrane may be applicable in cancer therapy. *Med. hypotheses*. 2008;70(4): 812-814.

16. Farahidhosseinabadi B, Farahani M, Tayebi T, et al. Amniotic membrane and its epithelial and mesenchymal stem cells as an appropriate source for skin tissue engineering and regenerative medicine. *Artif Cells Nanomed Biotechnol*. 2018;46(sup2):431-440.

17. Tehrani FD, Firouzeh A, Shabanl I, Shabanl A. A review on modifications of amniotic membrane for biomedical applications. *Front Bioeng Biotechnol*. 2020;8:609682.

18. Meller D, Paulklin M, Thomasen H, Westekemper H, Steuhl KP. Amniotic membrane transplantation in the human eye. *Dtsch Arztebl Int*. 2011;108(14):243.

19. Kitagawa K, Yanagisawa S, Watanabe K, et al. A hyperdry amniotic membrane patch using a tissue adhesive for corneal perforations and bleb leaks. *Am J Ophthalmol*. 2009;148(3):383-389.

20. Kitagawa K, Okabe M, Yanagisawa S, Xue-Yun Z, Nikaido T, Hayashi A. Use of a hyperdried cross-linked amniotic membrane as initial therapy for corneal perforations. *Jpn J Ophthalmol*. 2011;55(1):16-21.

21. Shojaku H, Takakura H, Okabe M, Fujisaka M, Watanabe Y, Nikaido T. Effect of hyperdry amniotic membrane patches attached over the bony surface of mastoid cavities in canal wall down tympanoplasty. *Laryngoscope*. 2011;121(9):1953-1957.

22. Seitz B, Das S, Sauer R, Hofmann-Rummelt C, Beckmann MW, Kruse FE. Simultaneous amniotic membrane patch in high-risk keratoplasty. *Cornea*. 2011;30(3):269-272.

23. Mao Y, Hoffman T, Johnson A, Duan-Arnold Y, Danilkovitch A, Kohn J. Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds. *J Diabet Foot Complicat*. 2016;8(2):23-30.

24. Orman S, Yol S, Uzun H, Ceyran AB, Eyüboğlu F. Effect of acellular amniotic membrane matrix patch on healing of cut surface after sleeve gastrectomy in rats. *J Invest Surg*. 2020;33(1):97-105.

25. Navas A, Magaña-Guerrero FS, Dominguez-López A, et al. Anti-inflammatory and anti-fibrotic effects of human amniotic membrane mesenchymal stem cells and their potential in corneal repair. *Stem Cells Trans Med*. 2018;7(12):906-917.

26. Charles-Henri W, Ekaterine B. Immunomodulatory properties of amniotic membrane derivatives and their potential in regenerative medicine. *Curr Diab Rep*. 2020;20(8):31.

27. Yadav MK, Go YY, Kim SH, Chae SW, Song JJ. Antimicrobial and antibiofilm effects of human amniotic/chorionic membrane extract on *Streptococcus pneumoniae*. *Front Microbiol*. 2017;8:1948.

28. Faraj LA, Stewart EA, Albert R, et al. In vitro anti-angiogenic effects of cryo-preserved amniotic membrane and the role of TIMP2 and thrombospondin. *J Exp Cornea*. 2018;1(1):3-7.

29. Zali H, Jafari A. Anticancer properties of amniotic membrane epithelial cells. *J Glob Pharma Technol*. 2016;8(12):22-29.

30. McDonald CA, Payne NL, Sun G, et al. Immunosuppressive potential of human amnion epithelial cells in the treatment of experimental autoimmune encephalomyelitis. *J Neuromimflammation*. 2015;12(1):112.

31. Vosdoganes P, Hodges RJ, Lim R, et al. Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep. *Am J Obstet Gynecol*. 2011;205(2):156.e26-e33.

32. Barbani B, Russo V, Curini V, et al. Gestational stage affects amniotic epithelial cells phenotype, methylation status, immunomodulatory and stemness properties. *Stem Cell Rev Rep*. 2014;10(5):725-741.

33. Magatti M, Caruso M, De Munari S, et al. Human amniotic membrane-derived mesenchymal and epithelial cells exert different effects on monocyte-derived dendritic cell differentiation and function. *Cell Transplant*. 2015;24(9):1733-1752.

34. Jafari A, Rezaei-Tavirani M, Farahidhosseinabadi B, Zali H, Niknejad H. Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin. *Stem Cell Res Ther*. 2021;12(1):1-11.

35. Bauer D, Wasmuth S, Hennig M, Baecheil H, Steuhl KP, Heilinghaus A. Amniotic membrane transplantation induces apoptosis in T lymphocytes in murine corneas with experimental herpetic stromal keratitis. *Invest Ophthalmol Vis Sci*. 2009;50(7):3188-3198.

36. Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. *J Immunol*. 2013;191(11):5515-5523.

37. Li H, Niederkorn JY, Neelam S, et al. Immunosuppressive factors secreted by human amniotic epithelial cells. *Investigat Ophthalmol Vis Sci*. 2005;46(3):900-907.

38. Niknejad H, Yazdanapanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. *Cell Tissue Res*. 2016;363(3):599-608.

39. Hossain L, Siddika A, Adnan M, Diba F, Hasan Z, Asaduzzaman S. Human amniotic membrane and its anti-cancer mechanism: a good hope for cancer therapy. *SN Comp Clin Med*. 2019;1(7):487-495.

40. Modaresifar K, Azizian S, Zolghadr M, Moravvej H, Ahmadiani A, Niknejad H. The effect of cryopreservation on anti-cancer activity of human amniotic membrane. *Cryobiol*. 2017;74:61-67.

41. Riedel R, Pérez-Pérez A, Carmona-Fernández A, et al. Human amniotic membrane conditioned medium inhibits proliferation and modulates related microRNAs expression in hepatocarcinoma cells. *Sci Rep*. 2019;9(1):1-20.

42. Nugroho AE, Hermawan A, Putri DDP, Novika A, Meiyanto E. Modulation of Ficus septica Burm. F. and doxorubicin chemotherapy on T47D breast cancer cells. *Asian Pac J Trop Biomed*. 2013;3(4):297-302.

43. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification in invasive Breast Carcinoma. *Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*. Elsevier Inc.; 2014:934-951.

44. Sahin A, Zhang H. *Invasive Breast Carcinoma. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*. Elsevier Inc.; 2014:934-951.

45. Park SY, Choi JH, Nam JS. Targeting cancer stem cells in triple-negative breast cancer. *Cancers*. 2019;11(7):965.
46. Murad H, Hawat M, Ekhtiar A, et al. Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa. *Cancer Cell Int*. 2016;16(1):1-11.

47. Babajani A, Soltani P, Jamshidi E, Farjoo MH, Niknejad H. Recent advances on drug-loaded mesenchymal stem cells with anti-neoplastic agents for targeted treatment of cancer. *Front Bioeng Biotechnol*. 2020;8:748.

48. Niknejad H, Khayat-khoei M, Yazdanpanah G, Peirovi H. Evaluation of cytotoxic effects of condition medium from amniotic epithelial cells on cancer cell lines HeLa and MDA-MB-231. *Physiol Pharmacol*. 2013;17(2):156-163.

49. Lalier L, Pedelaborde F, Braud C, Menanteau J, Vallette FM, Olivier C. Increase in intracellular PGE 2 induces apoptosis in Bax-expressing colon cancer cell. *BMC Cancer*. 2011;11(1):153.

50. Pianta S, Signoroni PB, Muradore I, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. *Stem Cell Rev*. 2015;11(3):394-407.

51. Mills CC, Kolb E, Sampson VB. Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. *Cancer Res*. 2018;78(2):320-325.

52. Lu WJ, Peng W, Sun QQ, et al. # 2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models. *Cell Death Discov*. 2018;4(1):1-11.

53. Mamede A, Guerra S, Laranjo M, et al. Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma. *Med Oncol*. 2015;32(12):257.

54. Di Germanio C, Bernier M, Petr M, Mattioli M, Barboni B, de Cabo R. Conditioned medium derived from rat amniotic epithelial cells confers protection against inflammation, cancer, and senescence. *OncoTarget*. 2016;7(26):39051.

55. Devreotes P, Horwitz AR. Signaling networks that regulate cell migration. *Cold Spring Harb Perspect Biol*. 2015;7(8):a005959.

56. Ruiz-Cañada C, Bernabé-García A, Liarte S, et al. Amniotic membrane stimulates cell migration by modulating transforming growth factor-β signalling. *J Tissue Eng Regen Med*. 2018;12(3):808-820.

57. Bernabé-García A, Liarte S, Moraleda JM, Castellanos G, Nicolás FJ. Amniotic membrane promotes focal adhesion remodeling to stimulate cell migration. *Sci Rep*. 2017;7(1):1-12.

58. Alcaraz A, Mrowiec A, Insuastil CL, et al. Amniotic membrane modifies the genetic program induced by TGFβ, stimulating keratinocyte proliferation and migration in chronic wounds. *PLoS One*. 2015;10(8):e0135324.

59. Zhang Q, Bu S, Sun J, et al. Paracrine effects of human amniotic epithelial cells protect against chemotherapy-induced ovarian damage. *Stem Cell Res Ther*. 2017;8(1):270.

60. Niknejad H, Paeini-Vayghan G, Tehrani F, Khayat-Khoei M, Peirovi H. Side dependent effects of the human amnion on angiogenesis. *Placenta*. 2013;34(4):340-345.

61. Beaver CM, Ahmed A, Masters JR. Clonogenicity: holoclones and meroclones contain stem cells. *PLoS One*. 2014;9(2):e89834.

62. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. *J Biomed Sci*. 2018;25(1):20.

63. Huang Z, Yu P, Tang J. Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. *OncoTargets Ther*. 2020;13:5395-5405.

64. Bahmad HF, Cheaito K, Challhoub RM, et al. Sphere-formation assay: three-dimensional in vitro culturing of prostate cancer stem/progenitor sphere-forming cells. *Front Oncol*. 2018;8:347.

65. Wang C, Tang Z, Zhao Y, Yao R, Li L, Sun W. Three-dimensional in vitro cancer models: a short review. *Biofabrication*. 2014;6(2):022001.